Clinical Trial

A Phase III Study Evaluating the Efficacy and Safety of HRS9531 Injection in Subjects With Obstructive Sleep Apnea (OSA) and Obesity

Recruiting Phase 3
View on ClinicalTrials.gov →
Summary
A Phase III Study Evaluating the Efficacy and Safety of HRS9531 Injection in Subjects with Obstructive Sleep Apnea (OSA) and Obesity
Protocol Amendment History 1 amendment
This ClinicalTrials.gov record has been amended once since 2025-05-14.
Status change: Not Yet Recruiting → Recruiting 2025-11-14
Trial Details
NCT Number NCT06974851
Lead Sponsor Fujian Shengdi Pharmaceutical Co., Ltd.
Conditions Bstructive Sleep Apnea (OSA) and Obesity
Enrollment 140 participants
Start Date 2025-07-25
Primary Completion 2026-12 (estimated)
Study Completion 2026-12 (estimated)
Updated on ClinicalTrials.gov 2025-11-17